Myrtil Biotechnologies – innovating drug discovery for patients with dilated cardiomyopathy
In a long-term collaboration, Ksilink and myriamed jointly established and validated an induced pluripotent stem cell (i…
In a long-term collaboration, Ksilink and myriamed jointly established and validated an induced pluripotent stem cell (i…
Molecular Health and collaborators at the University of Florida College of Pharmacy, Takeda Oncology, and thinkQ2 publis…
Developed at the Institute of Bioorganic Chemistry of the Polish Academy of Sciences, alongside Mitsubishi Electric, Lab…
First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hype…
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) base…
First-ever development of an RNA therapeutic for heart failure Successful translation of unique scientific discovery int…
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) base…
First-in-class compound showed excellent tolerability and safety Unique mode of action in chronic heart failure confirm…
Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international r…
Researchers from the European Molecular Biology Laboratory in Heidelberg and Stanford University have found the cause of…